New combo shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT05171660
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and bevacizumab helps people with a specific type of advanced colorectal cancer (RAS-mutant, MSS) live longer without their cancer growing. About 446 adults who have not had prior treatment will be randomly assigned to receive either the standard therapy or the standard therapy plus sintilimab. The study aims to see if the combination improves outcomes like tumor shrinkage and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xuefeng Fang
Hangzhou, Zhejiang, 310009, China